Growth Factor Research Peptides Guide

This guide covers 5 research peptides in the Growth Factor category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.

IGF-1 LR3, a modified variant of insulin-like growth factor 1 (IGF-1), features an extended N-terminal sequence and a critical substitution that enhances its bioavailability. With a significantly prolonged half-life of 20-30 hours compared to the 12-15 hours of native IGF-1, studies suggest that this modification results in approximately threefold greater potency. This peptide has been primarily investigated in preclinical models for its anabolic properties, particularly in contexts related to body composition and injury recovery. However, it is important to note that IGF-1 LR3 remains a research compound, lacking clinical trials aimed at therapeutic use, and is prohibited by the World Anti-Doping Agency (WADA) due to its performance-enhancing effects.

Follistatin 344 has garnered attention in the realm of muscle growth due to its ability to inhibit myostatin, a known regulator of muscle mass. This inhibition allows for enhanced muscle hypertrophy, making it a target of interest in gene therapy applications. Notably, the AAV1-FS344 gene therapy has completed Phase I/II trials for conditions such as Becker muscular dystrophy and inclusion body myositis, as reported by Mendell et al. in 2015 and 2017, respectively. However, the recombinant protein version available from research suppliers has not undergone human clinical trials, limiting the available data on its efficacy and safety. Thus, while the potential applications in body composition are promising, the current evidence is primarily derived from animal models and gene therapy studies.

Mechano Growth Factor (MGF) is a splice variant of IGF-1 that plays a critical role in muscle repair and regeneration following mechanical stress. Produced in response to muscle damage, MGF activates satellite cells, which are essential for muscle growth and recovery. The synthetic form of MGF, however, has a very short half-life of only minutes in vivo, which poses challenges for its practical application. This limitation is somewhat mitigated by the PEGylated version, PEG-MGF, which has a longer duration of action. Despite its potential, MGF remains a research-only compound, with no clinical trials conducted to date, and is classified as a prohibited substance by WADA.

IGF-1 DES (Des(1-3)IGF-1) is a truncated variant of IGF-1 that exhibits enhanced potency due to its reduced binding affinity for IGF binding proteins (IGFBPs). This modification allows for a tenfold increase in efficacy at the IGF-1 receptor in specific tissue contexts, particularly in the brain where it is naturally produced. Despite its promising characteristics, IGF-1 DES has not been subjected to clinical trials, limiting its application to research environments. As a result, while it shows potential for various research applications, including muscle physiology studies, the absence of human data necessitates caution in interpreting its effects. Furthermore, it is classified as a banned substance by WADA.

Insulin-like Growth Factor 1 (IGF-1) is a 70-amino acid protein that plays a vital role in growth and metabolic processes throughout life. Primarily synthesized in the liver in response to growth hormone, IGF-1 mediates many of the anabolic effects attributed to growth hormone. The FDA has approved IGF-1, marketed as Increlex (mecasermin), for the treatment of severe primary IGF-1 deficiency, underscoring its clinical relevance. This approval is supported by robust clinical evidence demonstrating its efficacy in promoting growth in affected individuals. However, while IGF-1 serves as a critical reference point in research, it is essential to differentiate between its approved therapeutic use and the research-grade variants that may not have undergone similar validation.